When asked about her 3 wishes for the future of obesity care, Donna Ryan, MD, told Patient Care that she had just one: access.
For the 1 in 3 individuals with hyperlipidemia who can't or won't take a statin, preventive cardiologist Elizabeth Klodas, MD, details 3 alternative drug classes.
The ACIP voted on recommendations for monovalent SARS-CoV-2 vaccine booster shots, lowering the age for pneumonia vaccination, and next steps for clesrovimab for RSV.
Panelists discuss how real-world patient cases demonstrate the importance of individualizing obstructive sleep apnea treatment plans by considering factors such as disease severity, comorbidities, lifestyle, and patient preferences to optimize outcomes.
Eden Miller, DO, shares key takeaways on how personalized treatment helps in the management of diabetes.
Drs Tina Q. Tan and Rodney Rohde share final thoughts on addressing patient and parent concerns with COVID-19 vaccines.
Vials of tirzepatide 2.5 mg and 5 mg will be available with a prescription for the labeled drug through LillyDirect after completing a multistep verification process, the company said.
The potential adverse outcomes include asthma, food allergies, cerebral palsy, and cancer, according to a recent systematic review and meta-analysis.
In a large study of patients with COPD, a small increase in 5-year all-cause mortality risk was observed among those using roflumilast.
COVID-19 has dealt in-person addiction treatment a blow, but the chief medical officer of Groups Recover Together tells a telemedicine success story with a hybrid ending.
Train your staff well, says this expert in business texting solutions, and make sure to develop and use appropriate checks and balances.
Panelists discuss how early identification of Type 1 diabetes through screening programs, combined with emerging therapies like teplizumab, offers new opportunities for intervention and improved patient outcomes in at-risk populations.
Drs John Russell, Jacinda Abdul-Mutakabbir, Charles Vega, Wendy Wright, And Neil Skolnik provide their practice pearls and key thoughts on how to vaccinate their patient populations in the upcoming influenza season.
A recent American Kidney Fund survey of 300 primary care and specialty clinicians found ~15% of their patients had kidney disease of unknown origin.
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
Benjamin W. Friedman, MD, MS; Francesca Beaudoin, MD, MS, PhD; Paul Arnstein, RN, PhD, FAAN; and Jeff Gudin, MD, provide take-home messages to providers treating patients with acute pain.
Panelists discuss strategies for simplifying complex information for primary care physicians (PCPs), provide tips on how PCPs can effectively communicate evidence-based treatment options to patients, and outline actionable points and key takeaways to enhance patient care in managing menopause symptoms.
The coverage with evidence development (CED) policy requires enrollment in an active clinical trial for an adult to be eligible for Medicare coverage of treatment for Alzheimer's disease.
A concise update on legal status, FDA approvals, patient safety, and public perception.
Investigators identified 6 blood pressure patterns that, when combined with other risk factors, accurately stratified risk of hypertensive disorders of pregnancy.
Experts wrap up their discussion of emerging chronic kidney disease tests and treatments with key takeaways for providers and patients.
Panelists discuss how choosing topical treatments requires individualized therapy considering factors such as affected body areas, disease severity, patient age, formulation preferences, and insurance coverage.
Beginning on Sept 24, 2024, all women must be notified of their breast density status in mammography reports and encouraged to pursue supplemental screening.
Biosimilars Wyost and Jubobonti were approved as interchangeable for Xgeva and Prolia but launch will depend on the outcome of litigation between reference product manufacturers.
In an interview at AAD 2025, Katrina Abuabara, MD, stressed the importance of collaboration between primary care physicians and dermatologists.
If the FDA approves the treatment, it will be the first-ever MDMA-assisted therapy and psychedelic-assisted therapy. The PDUFA date is set for August 11, 2024.
Peer mentor programs can provide support for patients, especially when it comes to family planning and parenthood.
An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences
Health care leaders increasingly are looking to technology for solutions to the challenges facing primary care.